SCHEMBL12569372

SCHEMBL12569372

NCCC1=CCCCCC1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
ALOX15 P16050 2/20 0.46
ALDH1A1 P00352 5/20 0.46
USP2 O75604 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
EPHX1 P07099 1/20 0.41
PKM P14618 1/20 0.41
TAAR1 Q96RJ0 1/20 0.40
CXCR3 P49682 1/20 0.40
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14307127 1.00 SMN1; SMN2 (0.46) SMN1; SMN2ALOX15ALDH1A1USP2NPSR1
SCHEMBL132152 0.98
Ammonia Solution, Strong SCHEMBL6793670 0.95 ALDH1A1 (0.46) SMN1; SMN2ALOX15ALDH1A1USP2NPSR1
Hydrochloric Acid SCHEMBL1241910 0.95 ALDH1A1 (0.46) SMN1; SMN2ALOX15ALDH1A1USP2NPSR1
Bromide SCHEMBL31267150 0.95 ALDH1A1 (0.46) SMN1; SMN2ALOX15ALDH1A1USP2NPSR1
Iodide SCHEMBL31267157 0.95 ALDH1A1 (0.46) SMN1; SMN2ALOX15ALDH1A1USP2NPSR1
SCHEMBL12569379 0.91
SCHEMBL26027168 0.87 SMN1; SMN2 (0.44) SMN1; SMN2ALOX15ALDH1A1USP2NPSR1
SCHEMBL2513477 0.85 ALDH1A1 (0.52) SMN1; SMN2ALOX15ALDH1A1USP2NPSR1
SCHEMBL18652395 0.84 ALDH1A1 (0.44) SMN1; SMN2ALOX15ALDH1A1USP2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240189278-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. 2024-06-13 US disclosed
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. 2023-09-07 US disclosed
WO-2022011171-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. (US) 2022-01-13 WO disclosed
US-7964623-B2 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2011-06-21 US disclosed
US-7964623-B2 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2011-06-21 US disclosed
EP-1732929-B1 TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS NISSAN CHEMICAL IND LTD (JP) 2010-10-20 EP disclosed
US-20100069374-A1 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-03-18 US disclosed
US-20100069374-A1 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-03-18 US disclosed
US-7652008-B2 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-01-26 US disclosed
US-7652008-B2 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-01-26 US disclosed
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-03 US disclosed
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069374-A1 Tricyclic benzopyrane compound CBR1, CBR3, CYP2C9 SMN1; SMN2 2355/4885ALOX15 2356/4885ALDH1A1 2252/4885
US-20240189278-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION COL2A1, COL1A1, COL14A1 SMN1; SMN2 1343/4885ALOX15 2375/4885ALDH1A1 1583/4885
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents CBR1, CBR3, SCN8A SMN1; SMN2 2374/4885ALOX15 2135/4885ALDH1A1 2087/4885
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLKB1, KLK2, KLK1 SMN1; SMN2 4641/4885ALOX15 4062/4885ALDH1A1 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.